#Triveni_Bio
LightNews LightNews
newsen.bsky.social
Triveni Bio Secures $65 Million to Propel Innovative Bispecific TRIV-573 Clinical Studies and Company Expansion#United_States#Atopic_Dermatitis#Watertown#Triveni_Bio#TRIV-573
Triveni Bio Secures $65 Million to Propel Innovative Bispecific TRIV-573 Clinical Studies and Company Expansion
Triveni Bio has raised $65 million in Series C funding to advance its bispecific antibody clinical studies and enhance company growth, targeting atopic dermatitis.
third-news.com
June 17, 2026 at 11:12 AM
newsen.bsky.social
Triveni Bio Advances Bispecific Antibody TRIV-573 for Patients with Atopic Dermatitis#United_States#Atopic_Dermatitis#Triveni_Bio#TRIV-573#Watertown,_Massachusetts
Triveni Bio Advances Bispecific Antibody TRIV-573 for Patients with Atopic Dermatitis
Triveni Bio has initiated a Phase 1 clinical trial for TRIV-573, a bispecific antibody designed to treat atopic dermatitis through dual targeting mechanisms.
third-news.com
May 18, 2026 at 11:35 AM
newsen.bsky.social
Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment#USA#Atopic_Dermatitis#Watertown#Triveni_Bio#TRIV-509
Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment
Triveni Bio has begun a crucial Phase 2 clinical trial for TRIV-509, targeting atopic dermatitis, showcasing advancements in antibody treatments.
third-news.com
September 23, 2025 at 11:05 AM
newsen.bsky.social
Triveni Bio Commences First Phase 1 Trial for Atopic Dermatitis Treatment#USA#Watertown#Triveni_Bio#KLK5#TRIV-509
Triveni Bio Commences First Phase 1 Trial for Atopic Dermatitis Treatment
Triveni Bio announces the start of its Phase 1 clinical trial for TRIV-509, a promising treatment for atopic dermatitis, highlighting the importance of kallikreins.
third-news.com
May 21, 2025 at 11:04 AM